论文部分内容阅读
目的探讨那格列奈片治疗2型糖尿病的疗效和安全性。方法 56例2型糖尿病患者按随机分为治疗组(那格列奈组28例)和对照组(瑞格列奈组28例),治疗前后测定空腹血糖(FBG)、餐后2 h血糖(PBG)、糖化血红蛋白(HbAlc)及肝、肾功能等。结果治疗组显效率为46.4%,对照组50.0%,两组比较差异无显著性(P>0.05),治疗组有效率为46.4%,对照组46.4%,两组比较差异无显著性(P>0.05)。两组FBG、2h PBG、HbAlc均较各自治疗前下降(P<0.05);而两组间比较差异无显著性(P>0.05)。结论那格列奈片降糖效果好,与瑞格列奈相当,不良反应轻微,是一种有效安全的降糖药。
Objective To investigate the efficacy and safety of nateglinide in the treatment of type 2 diabetes mellitus. Methods 56 type 2 diabetic patients were randomly divided into treatment group (nateglinide group 28 cases) and control group (repaglinide group 28 cases). Before and after treatment, fasting blood glucose (FBG), postprandial blood glucose PBG), glycosylated hemoglobin (HbAlc) and liver and kidney function. Results The effective rate was 46.4% in the treatment group and 50.0% in the control group, with no significant difference between the two groups (P> 0.05). The effective rate was 46.4% in the treatment group and 46.4% in the control group, with no significant difference between the two groups (P> 0.05). The levels of FBG, 2h PBG and HbAlc in both groups were significantly lower than those before treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusion nateglinide tablets hypoglycemic effect is good, with repaglinide equivalent, minor adverse reactions, is an effective and safe hypoglycemic agents.